-
Product Insights
NewCardiac Ablation Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Cardiac Ablation Devices Pipeline Market Report Overview Cardiac ablation devices use radiofrequency energy to destroy cardiac tissues which propagate incorrect electrical signals to cause an abnormal heart rhythm. The cardiac ablation devices pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKX-019 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKX-019 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKX-019 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: NKX-019...
-
Product Insights
NewNet Present Value Model: Tyra Biosciences Inc’s TYRA-300
Empower your strategies with our Net Present Value Model: Tyra Biosciences Inc's TYRA-300 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PBCAR-19B in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PBCAR-19B in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PBCAR-19B in Mantle Cell Lymphoma Drug Details: PBCAR-19B is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PBCAR-20A in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PBCAR-20A in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PBCAR-20A in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PBCAR-20A in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PBCAR-20A in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PBCAR-20A in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PBCAR-19B in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PBCAR-19B in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PBCAR-19B in Diffuse Large B-Cell Lymphoma Drug Details: PBCAR-19B is...
-
Product Insights
Zika Virus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Zika Virus Infections - Drugs In Development, 2023’, provides an overview of the Zika Virus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Zika Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
B-Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘B-Cell Leukemia - Drugs In Development, 2023’, provides an overview of the B-Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Childhood Epilepsy – Drugs In Development, 2023
Global Markets Direct’s, ‘Childhood Epilepsy - Drugs In Development, 2023’, provides an overview of the Childhood Epilepsy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Childhood Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...